News | News By Subject | News by Disease News By Date | Search News

Edema/Swelling News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA     9/18/2014
Regeneron Pharmaceuticals, Inc. (REGN)'s Injection Eylea Recommended For Approval By CHMP     6/27/2014
Regeneron Pharmaceuticals, Inc. (REGN)'s Diabetic Eye Remedy Drug Impresses In Phase 3 Trial     2/11/2014
Regeneron Pharmaceuticals, Inc. (REGN)'s EYLEA® (aflibercept) Improves Vision in Another Eye Disorder     10/22/2013
ThromboGenics NV (TBGNF) Grabs Exclusive Rights to Bicycle Therapeutics Limited's Eye Treatment Technology     9/5/2013
Regeneron Pharmaceuticals, Inc. (REGN) Grabs EU Approval for New Use of EYLEA®     8/29/2013
Regeneron Pharmaceuticals, Inc. (REGN) and Bayer HealthCare AG (BAY) Report Positive One-Year Results From Two Phase 3 Trials of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema     8/8/2013
National Institute for Clinical Excellence (NICE) U-turns on Novartis AG (NVS)'s Lucentis for Diabetic Macular Oedema     10/5/2012
FDA Gives Second Approval to Regeneron Pharmaceuticals, Inc. (REGN)'s Eylea     9/25/2012
FDA Approves Roche (RHHBY)'s Lucentis to Treat Diabetic Macular Edema     8/10/2012
Ampio Pharmaceuticals, Inc. (AMPE) Says Eye Drug Shows Promise in Phase III Trials; Stock Rises +1.59(59.25%) @ 1:15PM EDT     3/20/2012
Celtic Pharma Completes Acquisition Of Exclusive Worldwide Rights To XERECEPT From Neurobiological Technologies, Inc. (NTII); NTI Receives $20 Million     11/29/2005

News from Around the Web

Press Releases
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial     6/13/2016
Araim Pharmaeuticals Release: Queen's University Belfast To Study The Innate Repair Activator ARA 290 In Diabetic Macular Edema     5/10/2016
Eleven Biotherapeutics (EBIO) To Present Data At The Association for Research in Vision & Ophthalmology 2016 Annual Meeting     4/29/2016
Remedy Pharmaceuticals, Inc. Announces Successful Completion Of End-Of-Phase II Meeting With FDA On A Novel Drug Treatment For CNS-Related Edema     3/4/2016
Allegro Ophthalmics LLC Announces Last Patient Enrolled In DEL MAR Phase IIb Clinical Trial Of Luminate For The Treatment Of Diabetic Macular Edema     1/5/2016
Aerpio Reports Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial     11/17/2015
EyeGate Pharma Announces Interim Data From Phase Ib/IIa Clinical Trial Of Iontophoretic EGP-437 Ophthalmic Solution In Macular Edema Patients     11/5/2015
Alimera Sciences (ALIM) Reports Second Quarter 2015 Financial Results     8/11/2015
Ultragenyx (RARE) Announces Initiation Of Phase II Study Of Recombinant Human Beta-Glucuronidase In Patients Under Five Years Old With Mucopolysaccharidosis 7     8/5/2015
Aerpio Announces Positive Results Of A Phase IIa Study Of AKB-9778 In Diabetic Macular Edema: The TIME-2 Trial     7/15/2015
Aerpio Announces Publication Of Positive Results Of Phase 1b/2a Clinical Trial Of Novel Tie2 Activator, AKB-9778, For The Treatment Of Patients With Diabetic Macular Edema (DME) – TIME-1 Study     3/4/2015
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema     12/4/2014
pSivida Corp (PSDV) Announces ILUVIEN® Receives Marketing Authorization In Italy For Treatment Of Chronic Diabetic Macular Edema     6/23/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: EYLEA® (Aflibercept) Injection Submitted For EU Marketing Authorization For The Treatment Of Patients With Macular Edema Secondary To Branch Retinal Vein Occlusion (BRVO)     6/11/2014
iCo Therapeutics Inc. Announces Top-Line Primary Endpoint Data From iCo-007 Phase 2 Ideal Study In Diabetic Macular Edema     6/9/2014

//-->